Published in N Engl J Med on October 09, 1997
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A (2003) 11.65
Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell (2010) 6.79
Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest (2007) 5.55
The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med (2002) 4.47
Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut (2000) 4.32
Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol (2010) 4.21
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21
Guidelines for the management of inflammatory bowel disease in adults. Gut (2004) 4.15
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
HIV infection and the gastrointestinal immune system. Mucosal Immunol (2008) 3.14
CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest (2003) 2.97
A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest (1999) 2.91
Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn's disease in adults. Dig Dis Sci (2012) 2.77
Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut (2006) 2.41
Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut (2005) 2.33
Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev (2002) 2.29
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut (2002) 2.26
Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut (1999) 2.24
Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med (2010) 2.15
Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol (2007) 2.10
Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci U S A (2011) 2.06
Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J Clin Invest (2003) 2.02
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut (2003) 1.95
Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut (2002) 1.94
Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut (2004) 1.87
TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol (2007) 1.85
Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol Blood Marrow Transplant (2009) 1.84
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut (2005) 1.84
Inflammatory bowel disease: past, present, and future. J Gastroenterol (2007) 1.83
TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc Natl Acad Sci U S A (2003) 1.82
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79
Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis (2002) 1.76
Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut (2000) 1.75
IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease. Inflamm Bowel Dis (2007) 1.71
Absence of bacterially induced RELMbeta reduces injury in the dextran sodium sulfate model of colitis. J Clin Invest (2006) 1.66
Critical role for tumor necrosis factor alpha in controlling the number of lumenal pathogenic bacteria and immunopathology in infectious colitis. Infect Immun (2001) 1.60
Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther (2006) 1.58
Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet (1999) 1.57
Inflammatory Bowel Disease. Dtsch Arztebl Int (2016) 1.56
Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis (2000) 1.56
Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther (2015) 1.53
Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol (2008) 1.52
Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther (2006) 1.45
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol (2015) 1.44
Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am J Pathol (2000) 1.42
MicroRNA regulation of intestinal epithelial tight junction permeability. Gastroenterology (2011) 1.41
Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut (2002) 1.41
Genome-wide expression profiling implicates a MAST3-regulated gene set in colonic mucosal inflammation of ulcerative colitis patients. Inflamm Bowel Dis (2011) 1.41
Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. J Gastroenterol (2012) 1.40
Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut (2002) 1.40
Adalimumab use in pregnancy. Gut (2005) 1.39
T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease. Gut (2004) 1.39
Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha. Gut (2004) 1.38
Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut (2004) 1.38
The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis (1999) 1.38
Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov (2010) 1.36
Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol (2006) 1.36
The relationship between heart rate variability and inflammatory markers in cardiovascular diseases. Psychoneuroendocrinology (2008) 1.35
The specific JNK inhibitor SP600125 targets tumour necrosis factor-alpha production and epithelial cell apoptosis in acute murine colitis. Immunology (2006) 1.34
Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol (2015) 1.34
Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut (2005) 1.33
Positive role of CCAAT/enhancer-binding protein homologous protein, a transcription factor involved in the endoplasmic reticulum stress response in the development of colitis. Am J Pathol (2009) 1.32
Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol (1999) 1.32
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis (2003) 1.31
Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin Exp Immunol (2003) 1.31
TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis (2004) 1.29
Anti-inflammatory effects of phosphatidylcholine. J Biol Chem (2007) 1.29
Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol (2000) 1.26
Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther (2010) 1.26
Defining the roles of perforin, Fas/FasL, and tumour necrosis factor alpha in T cell induced mucosal damage in the mouse intestine. Gut (2002) 1.25
Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut (2005) 1.25
Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Gut (2003) 1.24
The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci U S A (2005) 1.23
Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica (2009) 1.23
Cytokine regulation of epithelial permeability and ion transport. Gut (1999) 1.22
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol (2012) 1.22
Inflammation in the intestinal tract: pathogenesis and treatment. Dig Dis (2009) 1.21
TGF-beta/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. J Clin Invest (2001) 1.20
Retracted Biologic targeting in the treatment of inflammatory bowel diseases. Biologics (2009) 1.20
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J (2007) 1.19
NOD2 regulation of Toll-like receptor responses and the pathogenesis of Crohn's disease. Gut (2005) 1.17
Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut (2002) 1.17
Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun (2005) 1.15
Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies. Nat Med (2015) 1.15
Role of commensal and probiotic bacteria in human health: a focus on inflammatory bowel disease. Microb Cell Fact (2013) 1.14
In vivo demonstration of T lymphocyte migration and amelioration of ileitis in intestinal mucosa of SAMP1/Yit mice by the inhibition of MAdCAM-1. Clin Exp Immunol (2005) 1.13
Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn's disease. J Gastroenterol (2002) 1.13
The ICE inhibitor pralnacasan prevents DSS-induced colitis in C57BL/6 mice and suppresses IP-10 mRNA but not TNF-alpha mRNA expression. Dig Dis Sci (2007) 1.12
Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives. World J Gastroenterol (2014) 1.12
Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int (2010) 1.12
Crohn's disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli. Immunology (2007) 1.12
Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol (2007) 1.12
Critical role of endothelial P-selectin glycoprotein ligand 1 in chronic murine ileitis. J Exp Med (2006) 1.12
The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol (2010) 1.12
Monocyte/macrophage activation by normal bacteria and bacterial products: implications for altered epithelial function in Crohn's disease. Am J Pathol (2001) 1.11
Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathology. Proc Natl Acad Sci U S A (2011) 1.11
Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut (1998) 1.11
Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Gut (1999) 1.10
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 28.24
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis (2000) 6.90
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24
Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med (1994) 6.05
Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med (1990) 5.65
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 4.39
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21
Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology (1993) 4.14
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 3.85
Control of beta-catenin stability: reconstitution of the cytoplasmic steps of the wnt pathway in Xenopus egg extracts. Mol Cell (2000) 3.65
Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature (1985) 3.38
Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol (1994) 3.22
Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med (1980) 3.01
Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: a randomised placebo-controlled trial. Lancet (2001) 2.94
A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet (1999) 2.88
Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci U S A (1998) 2.88
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med (1990) 2.82
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis (2001) 2.80
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology (1999) 2.80
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med (2000) 2.78
Immunophysiology of experimental food allergy. Mucosal Immunol (2008) 2.76
Bulgeless dwarf galaxies and dark matter cores from supernova-driven outflows. Nature (2010) 2.71
Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology (1989) 2.66
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 2.62
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis (1999) 2.55
Incidence of AD may decline in the early 90s for men, later for women: The Cache County study. Neurology (2002) 2.52
Massive outbreak of antimicrobial-resistant salmonellosis traced to pasteurized milk. JAMA (1987) 2.47
Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology (1999) 2.46
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol (2001) 2.39
Human T cell hybridomas secreting factors for IgA-specific help, polyclonal B cell activation, and B cell proliferation. J Exp Med (1982) 2.27
Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology (1999) 2.25
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 2.23
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 2.21
Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol (2001) 2.20
Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology (1999) 2.15
Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet (1990) 2.13
Procoagulant and proinflammatory activity in acute coronary syndromes. Cardiovasc Res (1998) 2.12
Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther (2013) 2.12
Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology (1993) 2.03
Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. J Infect Dis (2000) 2.00
Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice. J Immunol (2001) 1.95
HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut (1999) 1.94
Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol (1999) 1.90
Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA (1993) 1.88
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology (1999) 1.84
The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol (1996) 1.83
Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am (1999) 1.82
Evidence for altered regulation of I kappa B alpha degradation in human colonic epithelial cells. J Immunol (1997) 1.80
Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther (2005) 1.79
Summary of a workshop on clindamycin colitis. J Infect Dis (1976) 1.78
Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis (1992) 1.73
American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12. Gastroenterology (1998) 1.71
Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med (1996) 1.70
Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol (1993) 1.70
Proinflammatory effects of IL-10 during human endotoxemia. J Immunol (2000) 1.69
Bacterial translocation in multiple organ failure: cause or epiphenomenon still unproven. Br J Surg (1997) 1.69
Molecular cloning of pertussis toxin genes. Nucleic Acids Res (1986) 1.64
Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med (1994) 1.64
Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med (1994) 1.63
Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy (2007) 1.60
Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood. Infect Immun (1994) 1.57
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology (2001) 1.57
Human malignant T cells capable of inducing an immunoglobulin class switch. J Exp Med (1985) 1.56
Inherited complement deficiency in children surviving fulminant meningococcal septic shock. Eur J Pediatr (1995) 1.53
Mixed triglyceride breath test: a noninvasive test of pancreatic lipase activity in the duodenum. Gastroenterology (1989) 1.52
Imparied lymphocyte responsiveness in inflammatory bowel disease. Gastroenterology (1973) 1.51
Elevated plasma concentrations of interferon (IFN)-gamma and the IFN-gamma-inducing cytokines interleukin (IL)-18, IL-12, and IL-15 in severe melioidosis. J Infect Dis (1999) 1.51
Prognostic value of cytokine concentrations (tumor necrosis factor-alpha, interleukin-6, and interleukin-10) and clinical parameters in severe melioidosis. J Infect Dis (2000) 1.50
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest (1994) 1.50
Interleukin 1 beta is expressed predominantly by enterocytes in experimental colitis. Gastroenterology (1991) 1.49
Clinical relevance of antibiotic-induced endotoxin release. Antimicrob Agents Chemother (1994) 1.48
Analysis of a positional candidate gene for inflammatory bowel disease: NRAMP2. Inflamm Bowel Dis (2000) 1.44
Short-term lymphocyte cultures in regional enteritis. Lancet (1970) 1.43
Pouchitis. Int J Colorectal Dis (1988) 1.40
Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severity. Gastroenterology (2000) 1.40
ACTH-induced adrenal hemorrhage: a complication of therapy masquerading as an acute abdomen. J Clin Gastroenterol (1990) 1.40
Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology (2001) 1.39
CXCL13 expression in the gut promotes accumulation of IL-22-producing lymphoid tissue-inducer cells, and formation of isolated lymphoid follicles. Mucosal Immunol (2009) 1.39
Physiologic cardiac hypertrophy corrects contractile protein abnormalities associated with pathologic hypertrophy in rats. J Clin Invest (1982) 1.38
Laparoscopic-assisted vs. open ileocolic resection for Crohn's disease. A comparative study. Surg Endosc (2000) 1.38
Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol (1997) 1.36
The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol (1998) 1.35
Persistent infection of human adenovirus type 5 in human monocyte cell lines. Virology (1992) 1.34